Petition the FDA & Congress to keep access to Compounded Semaglutide & Tirzepatide
Warning: Your Access to Semaglutide or Tirzepatide Could End Without Notice.
Mochi Health sued by both Novo Nordisk & Eli Lilly
Federal Judge Sides with FDA Over Compounders (OFA) in Lawsuit
Henry Meds Sued By Eli Lilly
Hims & Hers dropped from Novo Nordisk partnership
Empower Pharmacy Sued By Eli Lilly
81 U.S. Senators Urge FDA Action on GLP‑1s
Compounded versions contain identical medications to Ozempic/Wegovy and Zepbound/Mounjaro, costing 80-90% less. But here's the reality: The FDA shortage that allowed compounding has officially ended. Right now, pharmacies are operating in a legal gray zone that's rapidly closing. Major compounding pharmacies are already facing lawsuits from Novo Nordisk and Eli Lilly, and enforcement actions are beginning nationwide. Your provider likely hasn't communicated this clearly because they need to maintain cash flow while they still can. Once enforcement reaches your pharmacy, you'll need to either find $1,200+/month for branded drugs or discontinue treatment. This isn't speculation - it's already happening to patients across the country.
Most telehealth providers are financially incentivized to downplay risks to prevent mass cancellations. Many won't discuss this until they're forced to send termination notices. ProtectMyMeds exists to give you the unbiased truth about what's happening.
Yes - discontinuation clauses are standard. Telehealth companies have no legal obligation to continue your treatment. When compounding becomes restricted, they will likely pivot to selling branded medications such as Wegovy, Zepbound, Ozempic, and Mounjaro which have much higher costs.
You'll face two devastating options: 1) Stop treatment entirely, which studies show leads to rapid weight regain and metabolic disruption, or 2) Pay $1,200-1,500/month for branded Ozempic/Wegovy/Zepbound/Mounjaro. Most insurance won't cover it for weight loss.
Yes. While compounded medications are vulnerable in the general marketplace, ProtectMyMeds has established exclusive pharmacy partnerships. Eligible patients can sign a Reserve Supply Agreement (RSA), reserving their medication supply contractually in their name for up to 12 months, safeguarding against regulatory disruptions.
No, RSA availability varies according to state regulations and pharmacy licensing. After you sign our petition, a ProtectMyMeds access representative will clarify your options based on your location and circumstances.
Yes. Congressional action depends significantly on demonstrable public concern. Our petitions directly inform House and Senate committees, regulatory bodies, and public officials. Petition signers also receive priority consultation for securing RSAs.
Absolutely. ProtectMyMeds is a registered Public Benefit Corporation adhering strictly to HIPAA compliance standards. We never sell patient data. Your information is exclusively used for advocacy and connecting you securely with vetted pharmacy agreements.
We are on the front lines, fighting against restrictive legislation driven by pharmaceutical lobbying. We work to ensure lawmakers understand that access to affordable GLP-1s is a critical public health necessity, not a loophole to be closed.
We monitor the FDA, state pharmacy boards, and active litigation in real-time. We provide patients with the critical information and unbiased risk assessments that many providers intentionally withhold.
We identify, vet, and negotiate exclusive pathways for guaranteed long-term access. This includes facilitating access to Reserved Supply Agreements (RSAs), ensuring patients can secure their medication regardless of market instability and price hikes.